Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNASEQ Analysis of sh-TRC and sh-MIR100HG in the triplex negative breast cancer

ABSTRACT: Purpose:The goals of this study are using next generation sequencing to identify differentially expressed genes by analyzing knockdown of MIR100HG in triple-negative breast cancer

ORGANISM(S): Homo sapiens

PROVIDER: GSE107717 | GEO | 2018/12/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNASEQ Analysis of sh-TRC and sh-MIR100HG in the triplex negative breast cancer

Project description:RNASEQ Analysis of sh-TRC and sh-MIR100HG in the triplex negative breast cancer

| PRJNA421177 | ENA

RNAseq of triple negative breast cancer samples

Project description:We report RNAseq data from tumors obtained from patients with triple negative breast cancer Eight patients with II-III stageTNBC diagnosis (only one patient with IV oligometastatic stage) were included in the study. All patients received neoadjuvant chemotherapy based on sequential anthracyclines and taxanes ± platinum salts plus radiation therapy. Seven patients were evaluable for response and pathological complete response (RCB=0) was reached in 71.4% of the patients (2 patients with RCB=2). No patients received adjuvant systemic therapy.Tumor biopsies were obtained for RNAseq studies.

2022-10-20 | GSE206998 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of sh-NC and sh-Etv5 macrophage line Raw264.7 Transcriptomes

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare sh-NC with sh-Etv5 macrophage line Raw264.7 transcriptome profiling (RNA-seq).

2022-02-06 | GSE166294 | GEO

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of BALB/C mice triple-negative breast cancer Transcriptomes

Project description:Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare NGS-derived tumor transcriptome profiling (RNA-seq) to microarray and quantitative reverse transcription polymerase chain reaction (qRT–PCR) methods and to evaluate protocols for optimal high-throughput data analysis

2024-09-30 | GSE278201 | GEO

Metastasis in triple-negative breast cancer

Project description:Metastasis in triple-negative breast cancer

| PRJNA437929 | ENA

The Association of Genomic Lesions and PD-1/PD-L1 Expression in Resected Triple Negative Breast Cancers

Project description:We used DNA content-based flow cytometry to distinguish and isolate nuclei of clonal tumor populations from resected triple negative breast cancer tissues. We then interrogated each sorted tumor population with whole genome aCGH and next generation sequencing (NGS). The genomic data was correlated with IHC staining for PD-1 and PD-L1.

2018-11-15 | GSE107764 | GEO

LINC00461 binding protein in triple negative breast cancer

Project description:Using CHIRP-MS method to detect LINC00461 binding protein in MDA-MB-231 cell line of triple negative breast cancer

2023-04-04 | PXD041363 | iProX

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Project description:This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

| 2007227 | ecrin-mdr-crc

Heterogeneity of triple-negative breast cancer

Project description:Heterogeneity of triple-negative breast cancer was examined and compared across morphologic and molecular features

2018-01-01 | GSE97342 | GEO